HUP0000302A2 - OB fúziós protein készítmények és módszerek - Google Patents

OB fúziós protein készítmények és módszerek

Info

Publication number
HUP0000302A2
HUP0000302A2 HU0000302A HUP0000302A HUP0000302A2 HU P0000302 A2 HUP0000302 A2 HU P0000302A2 HU 0000302 A HU0000302 A HU 0000302A HU P0000302 A HUP0000302 A HU P0000302A HU P0000302 A2 HUP0000302 A2 HU P0000302A2
Authority
HU
Hungary
Prior art keywords
methods
fusion protein
protein compositions
compositions
derivative
Prior art date
Application number
HU0000302A
Other languages
English (en)
Inventor
Randy Ira Hecht
Michael Benjamin Mann
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of HUP0000302A2 publication Critical patent/HUP0000302A2/hu
Publication of HUP0000302A3 publication Critical patent/HUP0000302A3/hu
Publication of HU227088B1 publication Critical patent/HU227088B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)

Abstract

A jelen találmány Fc fúziós prőteinkészítményekkel, az ilyen,készítmények előállítására szőlgáló módszerekkel és ezekalkalmazásával kapcsőlatős. Részletesebben, a jelen találmány az OBprőtein vagy származék, vagy analóg N-terminális részéhez fűziőnált Fcimműnőglő-bűlin régiót vagy származékőt, vagy analógőt tartalmazó,genetikai vagy kémiai prőteinnel kapcsőlatős. ŕ
HU0000302A 1996-12-20 1997-12-11 Ob fusion protein compositions and process for producing thereof HU227088B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77097396A 1996-12-20 1996-12-20
PCT/US1997/023183 WO1998028427A1 (en) 1996-12-20 1997-12-11 Ob fusion protein compositions and methods

Publications (3)

Publication Number Publication Date
HUP0000302A2 true HUP0000302A2 (hu) 2000-06-28
HUP0000302A3 HUP0000302A3 (en) 2005-12-28
HU227088B1 HU227088B1 (en) 2010-06-28

Family

ID=25090296

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000302A HU227088B1 (en) 1996-12-20 1997-12-11 Ob fusion protein compositions and process for producing thereof

Country Status (26)

Country Link
EP (2) EP1835030A1 (hu)
JP (2) JP4175668B2 (hu)
KR (1) KR100937550B1 (hu)
CN (1) CN1195858C (hu)
AR (2) AR009436A1 (hu)
AT (1) ATE351910T1 (hu)
AU (1) AU5606098A (hu)
BG (1) BG64288B1 (hu)
BR (1) BR9713755A (hu)
CA (1) CA2275183A1 (hu)
CZ (1) CZ298203B6 (hu)
DE (1) DE69737266T2 (hu)
DK (1) DK0954588T3 (hu)
EA (2) EA004790B1 (hu)
ES (1) ES2280083T3 (hu)
HK (1) HK1021388A1 (hu)
HU (1) HU227088B1 (hu)
IL (1) IL130396A (hu)
NO (2) NO324506B1 (hu)
NZ (1) NZ514145A (hu)
PL (1) PL194159B1 (hu)
PT (1) PT954588E (hu)
RS (1) RS49927B (hu)
SK (1) SK287578B6 (hu)
WO (1) WO1998028427A1 (hu)
ZA (1) ZA9711239B (hu)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
ES2339846T3 (es) * 1995-11-22 2010-05-26 Amgen Inc. Metodo para aumentar la masa de tejido magro usando composiciones de proteina ob.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
AU7132798A (en) * 1997-04-17 1998-11-11 Amgen, Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
WO1999046283A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
PL219605B1 (pl) 1998-10-23 2015-06-30 Kirin Amgen Inc Dimeryczne mimetyki peptydów trombopoetynowych wiążące się z receptorem MP1 i wykazujące aktywność trombopoetyczną
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2001081377A2 (en) * 2000-04-21 2001-11-01 Amgen, Inc. Integrin/adhesion antagonists
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
CN100404673C (zh) 2001-02-19 2008-07-23 默克专利有限公司 鉴定t细胞表位的方法及制备具有降低的免疫原性的分子的用途
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
JP2002306163A (ja) * 2001-04-11 2002-10-22 Chemo Sero Therapeut Res Inst 大腸菌を宿主とする遺伝子組換えヒトトロンビンの調製方法
DE60237100D1 (de) 2001-10-22 2010-09-02 Amgen Inc Verwendung von leptin zur behandlung von lipoatropr prädisposition gegenüber der behandlung
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP3936673B2 (ja) * 2003-06-02 2007-06-27 国立大学法人群馬大学 Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
EA011859B9 (ru) 2004-01-05 2013-07-30 Емд Лексиген Ресерч Сентер Корп. Соединения для адресной доставки препарата к ткани или органу-мишени
JP5638177B2 (ja) 2004-02-11 2014-12-10 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP1773400A2 (en) 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
ATE548389T1 (de) 2004-08-03 2012-03-15 Innate Pharma Therapeutische und diagnostische verfahren und zusammensetzungen zum targeting von 4ig-b7-h3 und dem entsprechenden nk-zellen-rezeptor
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP1814590B2 (en) 2004-11-01 2013-12-11 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
KR101399178B1 (ko) * 2005-08-11 2014-06-18 아스트라제네카 파마수티컬스 엘피 선별가능한 특성을 갖는 하이브리드 폴리펩티드
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
KR101030612B1 (ko) 2005-10-21 2011-04-20 에프. 호프만-라 로슈 아게 폴리펩타이드의 재조합 발현 방법
EP1991577A2 (en) 2006-01-31 2008-11-19 Parkinson, John F. Modulation of mdl-1 activity for treatment of inflammatory disease
US8501686B2 (en) 2008-06-05 2013-08-06 University Of Michigan Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
CN102405230A (zh) 2009-04-22 2012-04-04 默克专利有限公司 具有修饰的FcRn结合位点的抗体融合蛋白
EP2464377B1 (en) 2009-08-14 2016-07-27 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Use of il-15 to increase thymic output and to treat lymphopenia
EP3241558B1 (en) 2010-09-28 2021-03-03 Aegerion Pharmaceuticals, Inc. Highly soluble leptins
EP2729160B1 (en) 2011-07-08 2019-03-27 Aegerion Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
EP3896759A1 (en) 2011-10-05 2021-10-20 OneD Material, Inc. Silicon nanostructure active materials for lithium ion batteries and processes, compositions, components, and devices related thereto
RU2650646C2 (ru) 2012-09-27 2018-04-16 Дзе Чилдрен'З Медикал Сентер Корпорейшн Соединения, предназначенные для лечения ожирения, и способы их применения
AU2014354831B2 (en) 2013-11-26 2017-10-26 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
MX2019002818A (es) 2016-09-12 2019-08-29 Aegerion Pharmaceuticals Inc Metodos para detectar anticuerpos neutralizantes anti-leptina.
CN110183530A (zh) * 2019-06-21 2019-08-30 深圳市亚辉龙生物科技股份有限公司 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用
CN112618698B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白的注射制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CA2196200A1 (en) * 1994-07-29 1996-02-15 Michael Joseph Browne Novel compounds
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JPH0870875A (ja) * 1994-09-05 1996-03-19 Tosoh Corp 組換えアルカリフォスファタ−ゼ融合タンパク質
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
ES2339846T3 (es) * 1995-11-22 2010-05-26 Amgen Inc. Metodo para aumentar la masa de tejido magro usando composiciones de proteina ob.
RU2178307C2 (ru) * 1995-12-27 2002-01-20 Джинентех Инк. Производные ов-протеина

Also Published As

Publication number Publication date
EP0954588A1 (en) 1999-11-10
NO992779D0 (no) 1999-06-08
DE69737266D1 (de) 2007-03-08
EA200100216A1 (ru) 2001-08-27
EP0954588B1 (en) 2007-01-17
BR9713755A (pt) 2000-02-01
WO1998028427A1 (en) 1998-07-02
ATE351910T1 (de) 2007-02-15
HUP0000302A3 (en) 2005-12-28
JP2001512417A (ja) 2001-08-21
HK1021388A1 (en) 2000-06-09
JP2008289487A (ja) 2008-12-04
NO324506B1 (no) 2007-11-05
AR009436A1 (es) 2000-04-12
EA004791B1 (ru) 2004-08-26
IL130396A (en) 2011-09-27
KR100937550B1 (ko) 2010-01-19
CA2275183A1 (en) 1998-07-02
CZ9902036A3 (cs) 2000-10-11
IL130396A0 (en) 2000-06-01
HU227088B1 (en) 2010-06-28
ZA9711239B (en) 1998-06-23
NO20071415L (no) 1999-08-19
CN1246154A (zh) 2000-03-01
PT954588E (pt) 2007-03-30
JP4659068B2 (ja) 2011-03-30
BG64288B1 (bg) 2004-08-31
CZ298203B6 (cs) 2007-07-18
EP1835030A1 (en) 2007-09-19
JP4175668B2 (ja) 2008-11-05
EA199900575A1 (ru) 2000-02-28
DK0954588T3 (da) 2007-05-14
NO325096B1 (no) 2008-02-04
CN1195858C (zh) 2005-04-06
ES2280083T3 (es) 2007-09-01
PL334242A1 (en) 2000-02-14
EA004790B1 (ru) 2004-08-26
BG103522A (en) 2000-03-31
AR059907A2 (es) 2008-05-07
RS49927B (sr) 2008-09-29
YU27999A (sh) 2000-10-30
SK287578B6 (sk) 2011-03-04
SK77499A3 (en) 2001-04-09
PL194159B1 (pl) 2007-05-31
NO992779L (no) 1999-08-19
AU5606098A (en) 1998-07-17
NZ514145A (en) 2003-08-29
KR20000069617A (ko) 2000-11-25
DE69737266T2 (de) 2007-11-08

Similar Documents

Publication Publication Date Title
HUP0000302A2 (hu) OB fúziós protein készítmények és módszerek
DK1149905T3 (da) Fremgangsmåder og præparat til polypeptidteknologi
BG102071A (en) Minor molecule inhibitors of rotamase enzymic activity
BR9507618A (pt) Frações polipeptidicas solúveis da proteína lag-3 processo de produção composição terapêutica anticorpos anti-idiotipo
CA2270289A1 (en) Proteins with enhanced levels of essential amino acids
DE68929043T2 (de) Für androgen-rezeptor-protein kodierende dna
ATE336511T1 (de) Peptide und peptidomimetika mit struktureller ähnlichkeit mit p53 und die die p53-funktion aktivieren
AU4162400A (en) Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
DE69735502D1 (de) Mutanten des lag-3 proteins, ihre expression und verwendung
SE8801701D0 (sv) Production technology based on enzymic method
DE68917837D1 (de) Peptid-Verbindungen.
ES2100960T3 (es) Estructura proteica de la toxina vegetal gelonina.
NO984491L (no) SCF-analogpreparater og fremgangsmÕte for fremstilling av disse
ATE314474T1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
MX9707973A (es) Lipasas preduodenales recombinantes y polipeptidos derivados producidos por las plantas, sus procedimientos de obtencion y sus utilizaciones.
DE69734596D1 (de) "smoothened" proteine aus wirbeltieren
EP0780472A3 (en) Stress proteins
DE68914397D1 (de) Menschliches Lymphotoxin.
DK0811068T3 (da) Humane DNase I varianter
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe
SE9604439D0 (sv) New receptor

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees